Tarsus Pharmaceuticals, Inc. Common Stock

TARSNASDAQ • USD
77.95 USD
↘ 2.33 (2.90%)🟢LIVE (AS OF 02:00 PM EST)
🟢Market: OPEN

Tarsus Pharmaceuticals, Inc. Common Stock (TARS) trades at $77.95 per share. There is a divergence between signals — technical indicators rate "Strong Buy" but underlying fundamentals lean "Sell". Notable factors include a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 1/9, negative Return on Equity and a bullish Golden Cross on the moving averages. Valuation-wise, the stock is priced at a premium — multiples like P/E and EV/EBITDA sit above sector averages.

Technical & fundamental data as of Nov 13, 2026.

Open?$81.35
High?$81.35
Low?$77.31
Prev. Close?$80.28
Volume?272.5K
Avg. Volume?960.1K
VWAP?$79.13
Rel. Volume?0.28x
Bid / Ask
Bid?$77.94 × 100
Ask?$89.46 × 100
Spread?$11.52
Midpoint?$83.70
Valuation & Ratios
Market Cap?4.0B
Shares Out?49.3M
Float?37.5M
Float %?85.6%
P/E Ratio?N/A
P/B Ratio?38.05
EPS?-$14.25
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.
Employees
370
Market Cap
4.0B
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Listed
2020-10-16
Address
15440 LAGUNA CANYON ROAD
IRVINE, CA 92618
Phone: (949) 409-9820
Technical OutlookStrong Buy
Strong SellNeutralStrong Buy
Long-Term (Tide)?▲ Bullish(+3/3)
Medium-Term (Wave)?▲ Bullish(+2/3)
Short-Term (Ripple)?▲ Bullish(+3/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
6
Z-Score?
3
Momentum?
60
Short Sent.?
20
Piotroski F-Score?1/9Weak
Altman Z-Score?0.14Distress
Confidence?64%Moderate
Full Fundamental Analysis →
Short InterestHigh
Short % of Float?16.16%High
Short Interest?6.1M
Days to Cover?6.9
Free Float37.5M
Avg Daily Volume874.5K
Settlement Date2026-10-30
Financial Health
Current Ratio?1.96Adequate
Quick Ratio?1.94Adequate
Cash Ratio?0.60Adequate
Debt/Equity?0.70Moderate
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score
60/100
P/E?
N/A▾
P/B?
Peers
100
S&P
3
38.05HIGH▾
P/S?
Peers
100
S&P
23
5.80FAIR▾
P/FCF?
Peers
100
S&P
3
122.0PRICEY▾
EV/EBITDA?
S&P
97
-5.6CHEAP▾
EV/Sales?
Peers
100
S&P
30
5.71FAIR▾
Returns & Efficiency
ROE?
S&P
3
-675.5%WEAK▾
ROA?
S&P
3
-139.0%WEAK▾
Cash Flow & Enterprise
FCF?$32.4M
Enterprise Value?$3.9B
Fundamentals ratios updated end of day